Immunotherapy for hepatobiliary malignancies: Progress and prospective

Qin, Lun‐Xiu

doi:10.1016/j.hbpd.2022.09.002

Cited by 7 publications

(2 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The functional enrichment analysis of the two modules revealed a common pathway enrichment associated with hepatitis B, Hepatitis C, the HIF-1 signaling pathway, and PD-L1-related pathways in cancer, these pathways were not only directly linked to HCC but also played roles in various aspects of HCC. Activation of the HIF-1 signaling pathway has been shown to promote HCC proliferation (Kung-Chun Chiu et al, 2019) and reduce HCC's sensitivity to chemotherapy and radiotherapy (Zhao et al, 2014;Hu et al, 2021;Bai et al, 2022), PD-L1 and its related receptors have implications for HCC immunotherapy Qin, 2022). In these molecules, many were closely associated with HCC.…”

Section: Discussionmentioning

confidence: 99%

Integration of meta-analysis and network pharmacology analysis to investigate the pharmacological mechanisms of traditional Chinese medicine in the treatment of hepatocellular carcinoma

Lin,

Guo,

Qin

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Background: This study will explore the therapeutic value of traditional Chinese medicine (TCM) in Hepatocellular Carcinoma (HCC) through meta-analysis, combined with network pharmacology analysis.Methods: The results of randomized controlled trials on TCM and HCC were retrieved and summarized from multiple databases. The effective active com-pounds and target genes of the high-frequency TCM were obtained using the TCMSP database, and disease targets of HCC were acquired through the public disease database. The network pharmacology analysis was used to get the core genes and investigate the potential oncogenic molecular mechanism.Results: A total of 14 meta-analysis studies with 1,831 patients suggested that therapy combined TCM is associated with better clinical efficacy and survival prognosis, as well as avoiding many adverse events. A total of 156 compounds, 247 herbal target genes and 36 core genes were identified. The function analysis suggested above genes may participate development in HCC through regulating some pathways, such as HIF-1 pathway and PD-L1 immune-related pathway.Conclusion: TCM, as a novel, safe, and effective multi-mechanism therapy, holds greater value in the treatment of HCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Integration of meta-analysis and network pharmacology analysis to investigate the pharmacological mechanisms of traditional Chinese medicine in the treatment of hepatocellular carcinoma

Lin,

Guo,

Qin

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…With the ongoing development of precision medicine, immunotherapeutic drugs, particularly immune checkpoint inhibitors (ICIs), have made breakthroughs in cancer treatment. Inhibitors of the programmed cell death protein 1 (PD-1)/ programmed death-ligand 1 (PD-L1) play an important therapeutic role in a wide range of tumors (6)(7)(8)(9). In the phase 3 TOPAZ-1 trial in 685 patients with advanced BTC, durvalumab (a PD-L1 inhibitor) in combination with gemcitabine and cisplatin improved OS compared to placebo plus chemotherapy (median OS: 12.8 months vs 11.5 months, P=0.021) (10).…”

Section: Introductionmentioning

confidence: 99%

Immune-related adverse events correlate with the efficacy of PD-1 inhibitors combination therapy in advanced cholangiocarcinoma patients: A retrospective cohort study

Zhang

Wang

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

BackgroundWhether irAEs can predict the efficacy of PD-1 inhibitors in cholangiocarcinoma (CCA) has not been assessed. Therefore, this study aims to investigate the correlation between irAEs and the therapeutic effect of PD-1 inhibitors combination therapy in patients with advanced CCA.MethodsAll patients with CCA who were consecutively admitted to the inpatient unit of our hospital and received PD-1 inhibitors combination therapy between September 2020 and April 2022 were screened. In total, 106 patients with CCA were screened out. We then followed up these patients until October 2022. Due to perioperative use (n=28), less than 2 cycles of PD-1 inhibitor therapy (n=9), incomplete data (n=8) and no pathological report (n=2), 59 patients were included in the final analysis. The patients were divided into the irAEs cohort and the non-irAEs cohort according to whether they experienced irAEs or not. The Log-Rank test was performed to compare the difference in survival time between these two cohorts. We then applied multivariate COX regression analysis to investigate whether irAEs were independent prognostic factors for survival in patients with advanced CCA.ResultsFinally, 32 patients were included in the irAEs cohort and 27 patients in the non-irAEs cohort. A total of 32 patients (54.2%) had any-grade irAEs, of which 4 patients (6.8%) had grade 3-4 irAEs. The most common irAEs were thyroid toxicity (30.5%) and dermatologic toxicity (30.5%). There were no notable differences in demographics and clinical characteristics between the irAEs and non-irAEs cohorts, except for total bilirubin level (P=0.026) and relapse (P=0.016). The disease control rate (DCR) in the irAEs cohort was higher than in the non-irAEs cohort (90.6% vs 70.4%, P=0.047). Median overall survival (OS) and median progression-free survival (PFS) were better in the irAEs cohort than in the non-irAEs cohort (OS: 21.2 vs 10.0 months, P<0.001; PFS: 9.0 vs 4.4 months, P=0.003). Multivariate COX regression analysis showed that irAEs were independent prognostic factors for OS and PFS (OS: HR=0.133, 95% CI: 0.039-0.452, P=0.001; PFS: HR=0.435, 95% CI: 0.202-0.934, P=0.033).ConclusionIrAEs correlated with improved DCR, OS, and PFS in advanced CCA patients receiving PD-1 inhibitors combination therapy.

show abstract

Oncogenic Wnt3a is a promising sensitive biomarker for monitoring hepatocarcinogenesis

Yao¹,

Wang²,

Chen³

et al. 2023

Hepatobiliary & Pancreatic Diseases International

View full text Add to dashboard Cite

Immunotherapy for hepatobiliary malignancies: Progress and prospective

Cited by 7 publications

References 47 publications

Integration of meta-analysis and network pharmacology analysis to investigate the pharmacological mechanisms of traditional Chinese medicine in the treatment of hepatocellular carcinoma

Integration of meta-analysis and network pharmacology analysis to investigate the pharmacological mechanisms of traditional Chinese medicine in the treatment of hepatocellular carcinoma

Immune-related adverse events correlate with the efficacy of PD-1 inhibitors combination therapy in advanced cholangiocarcinoma patients: A retrospective cohort study

Oncogenic Wnt3a is a promising sensitive biomarker for monitoring hepatocarcinogenesis

Contact Info

Product

Resources

About